With Pfizer Inc. pivoting from seeking big M&A deals to grow to investing in internal R&D and smaller, earlier-stage transactions under new CEO Albert Bourla, its gene therapy unit is looking increasingly interesting as a crucible for innovation and potential growth.
The strategy has most recently seen it pay €45m for an option to buy France’s Vivet Therapeutics, with its...








